Prognostic value of peptidyl-prolyl cis–trans isomerase 1 (PIN1) in human malignant tumors
- 26 Downloads
PIN1, a peptidyl-prolyl cis–trans isomerase, specifically can regulate phosphorylation of proteins on serine/threonine residues that precede proline and has critical roles in cell proliferation and transformation. Many studies have revealed that overexpression of PIN1 is involved in the malignant biological behavior of various cancers, but to date, no meta-analyses have evaluated PIN1 clinical and prognostic value in patients with malignant tumors.
We retrieved related articles from PubMed, Web of Science and Scopus databases up to April 20, 2019. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were used to estimate the correlation of PIN1 expression with clinicopathological characteristics and survival outcomes. The methodology was according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Cochrane Collaboration guidelines.
A total of 20 studies containing 2574 patients with various tumors were included in this analysis. Pooled results showed that PIN1 overexpression was significantly associated with the advanced clinical stages of cancer (OR = 1.37, 95% CI 1.06–1.78), positive lymph node metastasis (OR = 1.65, 95% CI 1.15–2.37) and poor prognosis (HR = 2.40, 95% CI 1.55–3.74), although no correlation with poor differentiation was found.
These results suggest that high expression of PIN1 can be considered as a risk factor for progression and invasion of malignant tumors and thus may serve as a promising therapeutic target and prognostic biomarker for human solid tumors.
KeywordsPeptidyl-prolyl cis–trans isomerase 1 Meta‐analysis Prognostic marker Clinical characteristics
Peptidyl-prolyl cis–trans isomerase 1
Non-small cell lung cancer
Esophageal squamous cell carcinoma
Squamous cell carcinoma of cervix
Papillary thyroid carcinoma
Breast infiltrating duct carcinoma
Head and neck squamous cell carcinomas
Salivary adenoid cystic carcinoma
Merkel cell carcinoma
RN, SGK and CM were responsible for the conception and design of the review. SGK and CM conducted the database search and data collection. YM was responsible for the data analysis. SGK, CM and SS were involved in the interpretation of results and drafting the article. All the authors reviewed this draft, contributed and approved the final manuscript.
This study was supported by a grant from Hamadan University of Medical Sciences, Hamadan, Iran (9806054259).
Compliance with ethical standards
Conflict of interest
SGK, CM, YM, SS and RN declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study formal consent is not required.
- 8.Chen Y, Wu Y, Yang H, Li X, Jie M, Hu C, et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. Cell Death Dis. 2018;9(9):1–17.Google Scholar
- 45.Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Can Res. 2003;63(19):6244–51.Google Scholar